TY - JOUR
T1 - The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain
AU - Maravilla-Herrera, Paulina
AU - Merino, María
AU - Alfonso Zamora, Santiago
AU - Balea Filgueiras, Jesús
AU - Carrascosa, José Manuel
AU - Delgado Sánchez, Olga
AU - Dolz Sinisterra, Francisco
AU - García-Ruiz, Antonio
AU - Herranz Pinto, Pedro
AU - Manfredi, Antonio
AU - Martínez Olmos, José
AU - Morales de los Ríos Luna, Paloma
AU - Puig Sanz, Lluís
AU - Ros Abarca, Sandra
AU - Hidalgo, Álvaro
N1 - Publisher Copyright:
Copyright © 2023 Maravilla-Herrera, Merino, Alfonso Zamora, Balea Filgueiras, Carrascosa Carrillo, Delgado Sánchez, Dolz Sinisterra, García-Ruiz, Herranz Pinto, Manfredi, Martínez Olmos, Morales de los Ríos Luna, Puig, Ros and Hidalgo-Vega.
PY - 2023/1/26
Y1 - 2023/1/26
N2 - Introduction: Psoriasis is a chronic disease involving the skin, which significantly impacts the quality of life. Disease severity and treatment efficacy (i.e., response) are assessed through the Psoriasis Area and Severity Index (PASI). A PASI 75 response, i.e., an improvement of at least 75% with respect to the baseline PASI score, has traditionally been used as a therapeutic benchmark in clinical trials. Therapeutic advances have made PASI 90 or PASI 100 responses possible in most patients treated with some biologics. A greater response may generate social value beyond clinical outcomes that would benefit both patients and society. Methods: A 1-year economic model was applied to estimate the impact of having a PASI 75, PASI 90, or PASI 100 response in four areas of analysis (quality of life, activities of daily living, work productivity, and out-of-pocket expenditures) and the social value of having a PASI 90 or PASI 100 response in comparison with a PASI 75 response. A mixed-methods approach based on the scientific literature, a focus group with patient, and an advisory committee with psoriasis stakeholders was used. The model included three different scenarios: having a PASI 90 vs a PASI 75 response; a PASI 100 vs a PASI 90 response; and a PASI 100 vs a PASI 75 response. A sensitivity analysis was included. Results: The annual economic impact per patient with moderate-to-severe plaque psoriasis having a PASI 75 response was estimated at Ł 6,139, mainly related to labour productivity losses and quality of life reductions. Having a PASI 90 or a PASI 100 response would reduce this impact to €3,956 or €1,353, respectively. Accordingly, the social value of having a PASI 90 instead of a PASI 75 response was estimated at €2,183, and €4,786 with a PASI 100 response. Discussion: A PASI 90 or PASI 100 response would have a lower economic impact and a greater social value than a PASI 75 response for patients with moderate-to-severe plaque psoriasis.
AB - Introduction: Psoriasis is a chronic disease involving the skin, which significantly impacts the quality of life. Disease severity and treatment efficacy (i.e., response) are assessed through the Psoriasis Area and Severity Index (PASI). A PASI 75 response, i.e., an improvement of at least 75% with respect to the baseline PASI score, has traditionally been used as a therapeutic benchmark in clinical trials. Therapeutic advances have made PASI 90 or PASI 100 responses possible in most patients treated with some biologics. A greater response may generate social value beyond clinical outcomes that would benefit both patients and society. Methods: A 1-year economic model was applied to estimate the impact of having a PASI 75, PASI 90, or PASI 100 response in four areas of analysis (quality of life, activities of daily living, work productivity, and out-of-pocket expenditures) and the social value of having a PASI 90 or PASI 100 response in comparison with a PASI 75 response. A mixed-methods approach based on the scientific literature, a focus group with patient, and an advisory committee with psoriasis stakeholders was used. The model included three different scenarios: having a PASI 90 vs a PASI 75 response; a PASI 100 vs a PASI 90 response; and a PASI 100 vs a PASI 75 response. A sensitivity analysis was included. Results: The annual economic impact per patient with moderate-to-severe plaque psoriasis having a PASI 75 response was estimated at Ł 6,139, mainly related to labour productivity losses and quality of life reductions. Having a PASI 90 or a PASI 100 response would reduce this impact to €3,956 or €1,353, respectively. Accordingly, the social value of having a PASI 90 instead of a PASI 75 response was estimated at €2,183, and €4,786 with a PASI 100 response. Discussion: A PASI 90 or PASI 100 response would have a lower economic impact and a greater social value than a PASI 75 response for patients with moderate-to-severe plaque psoriasis.
KW - Social return
KW - Socioeconomic impact
KW - Psoriasis
KW - Psoriasis Area and Severity Index (PASI)
KW - Quality of life
KW - Out-of-pocket (OOP) expenses
KW - Activities of daily living
UR - http://www.scopus.com/inward/record.url?scp=85147771087&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/8e0a9871-8c6c-3ed9-88ca-f6e0b4b569af/
U2 - 10.3389/fpubh.2023.1000776
DO - 10.3389/fpubh.2023.1000776
M3 - Article
C2 - 36778548
SN - 2296-2565
VL - 11
JO - Frontiers in Public Health
JF - Frontiers in Public Health
M1 - 1000776
ER -